[go: up one dir, main page]

WO1991018003A1 - Derive antitumoral de be-13793c - Google Patents

Derive antitumoral de be-13793c Download PDF

Info

Publication number
WO1991018003A1
WO1991018003A1 PCT/JP1991/000214 JP9100214W WO9118003A1 WO 1991018003 A1 WO1991018003 A1 WO 1991018003A1 JP 9100214 W JP9100214 W JP 9100214W WO 9118003 A1 WO9118003 A1 WO 9118003A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
general formula
dihydro
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1991/000214
Other languages
English (en)
Japanese (ja)
Inventor
Masanori Okanishi
Daisuke Uemura
Seiichi Tanaka
Katsuhisa Kojiri
Akira Okura
Kohtaro Funaishi
Hiroyuki Suda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Priority to JP3504280A priority Critical patent/JP3064416B2/ja
Priority to CA002082528A priority patent/CA2082528C/fr
Priority to EP91904336A priority patent/EP0528030B1/fr
Priority to DE69127691T priority patent/DE69127691T2/de
Publication of WO1991018003A1 publication Critical patent/WO1991018003A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Definitions

  • the introduction and removal of the protecting group may be carried out by selecting an appropriate protecting group and introducing and removing the protecting group using a method commonly used in the relevant field.
  • the product of the above condensation reaction can be isolated and purified by methods known in the art, for example, solvent extraction, recrystallization, and chromatography.
  • the compound of the present invention represented by the general formula (I) exhibits excellent growth inhibitory activity against various cancer cells, and is a useful compound expected to be used as an antitumor agent.
  • pharmacological test examples will be described below.
  • BE-13793C (12,13-dehydro-dihydroxy-5H-indro [2,3-a] pyro [3,4-c] carbazole-5,7 (6H) -dione And Japanese Patent Application No. 2-71543).
  • various forms can be selected, for example, oral preparations such as tablets, capsules, powders, granules or liquids, or sterilizations such as solutions or suspensions. Liquid parenteral preparations.
  • Solid preparations can be produced as they are in the form of tablets, capsules, granules or powders, or they can be produced using appropriate additives.
  • additives include sugars such as lactose and glucose, starches such as corn, wheat and rice, fatty acids such as stearic acid, and inorganic salts such as magnesium aluminate metasilicate and anhydrous calcium phosphate.
  • BE-13793C (12,13-dihydro-1,11-dihydroxy-5H-indolo [2,3-a] pyrro [3,4-c] pyruvazole-5,7 (6H) -dione) 180.5 mg was dissolved in 37 mL of ⁇ , ⁇ -dimethylformamide (DMF), 510 mg of lithium carbonate was added, and then benzylbutamide 170 ⁇ ⁇ was added under ice cooling.
  • DMF ⁇ -dimethylformamide
  • BE-13793C represented by the formula ( ⁇ ) which is the starting compound of the compound of the present invention
  • the microorganism used to produce E. coli or a mutant thereof can produce the anti-neoplastic substance BE-13793C! ⁇ , although it may be shifted, for example, the BA-described in Japanese Patent Application No. 2-71543.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)
  • Fats And Perfumes (AREA)
  • Transplanting Machines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Dérivé de 12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-C]-carbazole-5,7(6H)-dione ayant la formule (I), son sel pharmaceutiquement admissible, sa production et ses utilisations. Dans la formule (I), R1 représente un groupe monosaccharide ayant entre 5 et 7 atomes de carbone. Les groupes hydroxyles du groupe monosaccharide peuvent être substitués par un à trois groupes identiques ou différents sélectionnés parmi hydrogène, alkyle inférieur, alkylcarbonyloxyle inférieur et alcoxyle inférieur.
PCT/JP1991/000214 1990-05-11 1991-02-20 Derive antitumoral de be-13793c Ceased WO1991018003A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP3504280A JP3064416B2 (ja) 1990-05-11 1991-02-20 抗腫瘍性物質ｂｅ―１３７９３ｃ誘導体
CA002082528A CA2082528C (fr) 1990-05-11 1991-02-20 Derives be-13793c d'une substance antitumorale
EP91904336A EP0528030B1 (fr) 1990-05-11 1991-02-20 Derive antitumoral de be-13793c
DE69127691T DE69127691T2 (de) 1990-05-11 1991-02-20 Be-13793c-derivat mit antitumorwirkung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2/122291 1990-05-11
JP12229190 1990-05-11

Publications (1)

Publication Number Publication Date
WO1991018003A1 true WO1991018003A1 (fr) 1991-11-28

Family

ID=14832324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1991/000214 Ceased WO1991018003A1 (fr) 1990-05-11 1991-02-20 Derive antitumoral de be-13793c

Country Status (6)

Country Link
EP (1) EP0528030B1 (fr)
JP (1) JP3064416B2 (fr)
AT (1) ATE158298T1 (fr)
CA (1) CA2082528C (fr)
DE (1) DE69127691T2 (fr)
WO (1) WO1991018003A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024491A1 (fr) * 1992-05-30 1993-12-09 Gödecke Aktiengesellschaft Indolocarbazol-imides et leur utilisation
US5437996A (en) * 1992-11-24 1995-08-01 Banyu Pharmaceutical Co., Ltd. Microtetraspora strain for preparation of indolopyrrolocarbazole derivatives
WO1995030682A1 (fr) * 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
US5547976A (en) * 1992-03-20 1996-08-20 Burroughs Wellcome Co. Further indole derivatives with antiviral activity
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5668271A (en) * 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
CN1035878C (zh) * 1992-02-18 1997-09-17 万有制药株式会社 吲哚并吡咯并咔唑衍生物
AU683749B2 (en) * 1994-05-09 1997-11-20 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5861293A (en) * 1994-06-13 1999-01-19 Banyu Pharmaceutical Co., Ltd. Gene encoding glycosyltransferase and its uses
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
GB2337702A (en) * 1998-05-29 1999-12-01 Merck Sharp & Dohme The use of staurosporine analogues for enhancing neurotrophin activity
JP3536574B2 (ja) 1997-02-28 2004-06-14 萬有製薬株式会社 抗腫瘍性インドロピロロカルバゾール誘導体
WO2005026185A1 (fr) * 2003-09-16 2005-03-24 Banyu Pharmaceutical Co., Ltd. Nouveau derive d'indolopyrrolocarbazole a active anti-tumeur

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083228A1 (fr) 1999-09-10 2004-09-30 Katsuhisa Kojiri Derives d'indolopyrrolocarbazole et agents antitumoraux

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269025A2 (fr) * 1986-11-21 1988-06-01 Bristol-Myers Squibb Company Analogues de rebeccamycine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3010675B2 (ja) * 1989-03-23 2000-02-21 萬有製薬株式会社 抗腫瘍性物質ｂｅ―１３７９３ｃ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269025A2 (fr) * 1986-11-21 1988-06-01 Bristol-Myers Squibb Company Analogues de rebeccamycine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Organic Chemistry Vol. 54, No. 4, Pages 824 to 828 (1989). *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5643760A (en) * 1991-11-29 1997-07-01 Banyu Pharmaceutical Co., Ltd. Microbial process for preparation of indolopyrrolocarbazole derivatives
US5668271A (en) * 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
CN1035878C (zh) * 1992-02-18 1997-09-17 万有制药株式会社 吲哚并吡咯并咔唑衍生物
US5547976A (en) * 1992-03-20 1996-08-20 Burroughs Wellcome Co. Further indole derivatives with antiviral activity
WO1993024491A1 (fr) * 1992-05-30 1993-12-09 Gödecke Aktiengesellschaft Indolocarbazol-imides et leur utilisation
US5437996A (en) * 1992-11-24 1995-08-01 Banyu Pharmaceutical Co., Ltd. Microtetraspora strain for preparation of indolopyrrolocarbazole derivatives
AU683749B2 (en) * 1994-05-09 1997-11-20 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
WO1995030682A1 (fr) * 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
JP3038921B2 (ja) 1994-05-09 2000-05-08 萬有製薬株式会社 抗腫瘍性インドロピロロカルバゾール誘導体
CN1106400C (zh) * 1994-05-09 2003-04-23 万有制药株式会社 抗肿瘤吲哚并吡咯并咔唑衍生物
US5861293A (en) * 1994-06-13 1999-01-19 Banyu Pharmaceutical Co., Ltd. Gene encoding glycosyltransferase and its uses
USRE37206E1 (en) * 1994-06-13 2001-06-05 Banyu Pharmaceutical Co, Ltd Gene encoding glycosyltransferase and its uses
JP3536574B2 (ja) 1997-02-28 2004-06-14 萬有製薬株式会社 抗腫瘍性インドロピロロカルバゾール誘導体
GB2337702A (en) * 1998-05-29 1999-12-01 Merck Sharp & Dohme The use of staurosporine analogues for enhancing neurotrophin activity
WO2005026185A1 (fr) * 2003-09-16 2005-03-24 Banyu Pharmaceutical Co., Ltd. Nouveau derive d'indolopyrrolocarbazole a active anti-tumeur

Also Published As

Publication number Publication date
ATE158298T1 (de) 1997-10-15
JP3064416B2 (ja) 2000-07-12
EP0528030A4 (en) 1993-03-24
CA2082528A1 (fr) 1991-11-12
DE69127691T2 (de) 1998-01-15
EP0528030B1 (fr) 1997-09-17
EP0528030A1 (fr) 1993-02-24
DE69127691D1 (de) 1997-10-23
CA2082528C (fr) 2001-03-13

Similar Documents

Publication Publication Date Title
JP3064416B2 (ja) 抗腫瘍性物質ｂｅ―１３７９３ｃ誘導体
NZ245203A (en) 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
JP4066389B2 (ja) モルホリニルアントラサイクリン誘導体
US5589365A (en) Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
US5536827A (en) Method for preparing antitumor substance BE-13793C derivatives
EP0602597A2 (fr) Procédé de préparation de dérivés d'indolopyrrolocarbazole
US4303785A (en) Antitumor anthracycline antibiotics
WO2001002408A1 (fr) Nouveaux composes xanthone, leur preparation et leur utilisation comme medicament
JP4029137B2 (ja) 新生理活性物質
WO2004083228A1 (fr) Derives d'indolopyrrolocarbazole et agents antitumoraux
JP4038245B2 (ja) 新規なフェナンスリジニウム誘導体
CA2533384A1 (fr) Derive d'indolopyrrolocarbazole et agent antitumoral
Baker et al. An evaluation of certain chain-extended analogs of 9-. beta.-D-arabinofuranosyladenine for antiviral and cardiovascular activity
EP1828196B1 (fr) Procédé stéréosélectif et formes cristallines de camptothecin
JPH05163292A (ja) ３’及び／又は４’位の水酸基を化学修飾したエルサマイシンａ誘導体の製造法
US4604381A (en) 4-demethoxy-13-dihydrodaunorubicin and use thereof
JP4334194B2 (ja) エクチナサイジン７８６およびその取得方法
JPS61143394A (ja) 新マクロライド誘導体
JP2907948B2 (ja) 新規なステロイド化合物および制癌剤
EP0760375A1 (fr) Derive d'indolopyrolocarbazole antitumoral
WO1998022612A1 (fr) Nouveaux composes antitumoraux et utilisation de ces derniers
JP4155150B2 (ja) 抗腫瘍性新規インドロピロロカルバゾール誘導体
JP2000178274A (ja) 抗腫瘍性物質ｂｅ−５４０１７及びその製造法
EP0456514B1 (fr) 2-Fluoronéplanocine et sa préparation
JPS6260397B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2082528

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991904336

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991904336

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991904336

Country of ref document: EP